. Author manuscript; available in PMC: 2020 Jul 1.

Published in final edited form as: Osteoporos Int. 2019 Oct 12;31(1):67–75. doi: 10.1007/s00198-019-05142-z

Table 2. Univariate associations between participant characteristics (at baseline) and adherence to anti-osteoporosis medication (AOM) over the 5 year follow-up period (Logistic regression).

	Adherence during follow-up
	Odds ratio	95% CI	p-value
Age (years)^a	0.96	(0.93,0.99)	0.01
Weight [log(kg)]^b	1.15	(0.52,2.51)	0.74
Height (cm)^c	1.01	(0.99,1.03)	0.42
Prior fracture (Y/N)	0.89	(0.67,1.17)	0.40
Parent broken hip (Y/N)	1.67	(1.23,2.26)	<0.01
Smoker (Y/N)	1.00	(0.61,1.64)	1.00
Taken corticosteroids (Y/N)	0.81	(0.54,1.23)	0.32
Rheumatoid arthritis (Y/N)	0.80	(0.50,1.27)	0.34
Alcohol consumption (Y/N)	0.57	(0.32,1.03)	0.06
DXA Scan (Y/N)	1.89	(1.33, 2.68)	<0.01
Total hip BMD T-score (SD)	1.02	(0.82,1.27)	0.85
Incident fracture (post baseline) (Y/N)	1.03	(0.76,1.40)	0.86
FRAX^® risk category (High/Low)^d	2.80	(1.21,6.50)	0.02

OR for each year higher in age

OR for each log(kg) increase in weight

OR for each cm increase in height

in a subgroup of study participants with a FRAX^® category using BMD